Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGENNASDAQ:BCACNASDAQ:CRBUNASDAQ:JSPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$4.47-6.5%$3.50$1.38▼$18.74$131.05M1.43661,369 shs615,634 shsBCACBrookline Capital Acquisition$2.95$0.86$9.50▼$27.74$19.90M-0.0339,682 shs29,998 shsCRBUCaribou Biosciences$1.28+10.3%$0.95$0.66▼$3.00$107.89M2.441.34 million shs1.25 million shsJSPRJasper Therapeutics$5.26-2.8%$4.98$3.13▼$26.05$81.27M2.72302,869 shs172,163 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus-7.00%-10.99%+37.36%+176.30%-66.57%BCACBrookline Capital Acquisition0.00%0.00%0.00%-87.01%-87.01%CRBUCaribou Biosciences+3.57%-4.92%+23.61%+21.99%-33.71%JSPRJasper Therapeutics-3.91%-6.24%+9.74%+4.24%-77.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGENAgenus4.0273 of 5 stars3.23.00.04.61.91.70.6BCACBrookline Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACRBUCaribou Biosciences2.762 of 5 stars3.53.00.00.02.61.70.6JSPRJasper Therapeutics2.2804 of 5 stars3.52.00.00.03.11.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGENAgenus 2.33Hold$14.00213.20% UpsideBCACBrookline Capital Acquisition 0.00N/AN/AN/ACRBUCaribou Biosciences 3.00Buy$8.50564.06% UpsideJSPRJasper Therapeutics 3.00Buy$62.221,082.93% UpsideCurrent Analyst Ratings BreakdownLatest BCAC, CRBU, JSPR, and AGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025AGENAgenusRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$4.00 ➝ $6.006/4/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$25.005/15/2025JSPRJasper TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$80.00 ➝ $65.005/13/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/13/2025AGENAgenusRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$3.00 ➝ $4.005/13/2025JSPRJasper TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $33.004/30/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/28/2025CRBUCaribou BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $3.004/21/2025AGENAgenusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/19/2025CRBUCaribou BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/18/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGENAgenus$103.46M1.18N/AN/A($13.06) per share-0.34BCACBrookline Capital AcquisitionN/AN/AN/AN/AN/AN/ACRBUCaribou Biosciences$9.99M11.92N/AN/A$2.79 per share0.46JSPRJasper TherapeuticsN/AN/AN/AN/A$4.11 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGENAgenus-$227.21M-$8.67N/AN/AN/A-196.12%N/A-82.33%8/6/2025 (Estimated)BCACBrookline Capital Acquisition-$480KN/A0.00∞N/AN/A-416.32%-4.75%N/ACRBUCaribou Biosciences-$149.10M-$1.62N/AN/AN/A-1,490.84%-55.70%-45.35%8/5/2025 (Estimated)JSPRJasper Therapeutics-$71.27M-$5.24N/AN/AN/AN/A-109.45%-89.82%8/12/2025 (Estimated)Latest BCAC, CRBU, JSPR, and AGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AGENAgenus-$1.61-$1.03+$0.58-$1.03$26.38 million$24.07 million5/12/2025Q1 2025JSPRJasper Therapeutics-$1.17-$1.41-$0.24-$1.41N/AN/A5/8/2025Q1 2025CRBUCaribou Biosciences-$0.43-$0.43N/A-$0.43$1.48 million$2.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGENAgenusN/AN/AN/AN/AN/ABCACBrookline Capital AcquisitionN/AN/AN/AN/AN/ACRBUCaribou BiosciencesN/AN/AN/AN/AN/AJSPRJasper TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGENAgenusN/A0.110.11BCACBrookline Capital AcquisitionN/A0.070.07CRBUCaribou BiosciencesN/A7.637.63JSPRJasper TherapeuticsN/A4.314.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGENAgenus61.46%BCACBrookline Capital Acquisition51.83%CRBUCaribou Biosciences77.51%JSPRJasper Therapeutics79.85%Insider OwnershipCompanyInsider OwnershipAGENAgenus5.50%BCACBrookline Capital Acquisition19.20%CRBUCaribou Biosciences8.28%JSPRJasper Therapeutics4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGENAgenus44027.42 million25.91 millionOptionableBCACBrookline Capital Acquisition66.75 million5.45 millionNot OptionableCRBUCaribou Biosciences10093.00 million85.30 millionOptionableJSPRJasper Therapeutics2015.02 million14.33 millionOptionableBCAC, CRBU, JSPR, and AGEN HeadlinesRecent News About These CompaniesJasper Therapeutics stock maintains buy rating on positive urticaria dataJune 18 at 7:54 PM | investing.comJasper Therapeutics Reports Encouraging Results from SPOTLIGHT Phase 1b/2a Study of Briquilimab for Chronic Inducible UrticariaJune 16 at 12:25 AM | nasdaq.comJasper Therapeutics’ SWOT analysis: briquilimab’s potential in CSU stock scrutinizedJune 15 at 7:19 PM | investing.comJasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible UrticariaJune 14, 2025 | globenewswire.comCantor Fitzgerald Comments on JSPR FY2026 EarningsJune 11, 2025 | americanbankingnews.comAnalysts Offer Predictions for JSPR FY2026 EarningsJune 10, 2025 | marketbeat.comJasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual CongressJune 3, 2025 | globenewswire.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of "Buy" by BrokeragesJune 1, 2025 | marketbeat.comJasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash WiselyMay 29, 2025 | finance.yahoo.comWoodline Partners LP Decreases Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR)May 26, 2025 | marketbeat.comJasper Therapeutics, Inc. (JSPR): Analysts See 914% Upside PotentialMay 21, 2025 | insidermonkey.comSoleus Capital Management L.P. Has $31.95 Million Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR)May 21, 2025 | marketbeat.comJasper Therapeutics to Present at RBC and Jefferies Global Healthcare Conferences on Briquilimab DevelopmentMay 16, 2025 | nasdaq.comJasper Therapeutics to Present at Upcoming Investor ConferencesMay 14, 2025 | globenewswire.comJasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 12, 2025 | globenewswire.comWhy Jasper Therapeutics, Inc.’s (JSPR) Stock Is Down 5.34%May 6, 2025 | aaii.comWhy Jasper Therapeutics, Inc.’s (JSPR) Stock Is Up 7.05%April 22, 2025 | aaii.comWhy Jasper Therapeutics, Inc.’s (JSPR) Stock Is Up 7.55%April 11, 2025 | aaii.comJasper Therapeutics inks new sales agreement, ends previous dealMarch 21, 2025 | uk.investing.comJasper Therapeutics files $300M mixed securities shelfMarch 19, 2025 | markets.businessinsider.comJasper Therapeutics presents updated data from Phase 1b/2a BEACON studyMarch 2, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCAC, CRBU, JSPR, and AGEN Company DescriptionsAgenus NASDAQ:AGEN$4.47 -0.31 (-6.49%) Closing price 04:00 PM EasternExtended Trading$4.41 -0.06 (-1.34%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Brookline Capital Acquisition NASDAQ:BCACBrookline Capital Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to acquire companies in the life sciences sector. The company was incorporated in 2020 and is based in New York, New York.Caribou Biosciences NASDAQ:CRBU$1.28 +0.12 (+10.34%) Closing price 04:00 PM EasternExtended Trading$1.26 -0.02 (-1.17%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.Jasper Therapeutics NASDAQ:JSPR$5.26 -0.15 (-2.77%) Closing price 04:00 PM EasternExtended Trading$5.26 0.00 (-0.10%) As of 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
